Literature DB >> 7388745

The prognostic significance of ulceration of cutaneous melanoma.

C M Balch, J A Wilkerson, T M Murad, S J Soong, A L Ingalls, W A Maddox.   

Abstract

Ulceration of a cutaneous melanoma on microscopic sections is an adverse prognostic finding. The five-year survival rate is reduced from 80% for non-ulcerated melanomas to 55% in the presence of ulceration for Stage I melanoma patients and from 53 to 12% for Stage II melanoma patients (P less than 0.001). As a group, ulcerated lesions are thicker and more likely to have a nodular growth pattern. However, survival rates were still worse for ulcerated melanomas when matched with nonulcerated lesions for thickness and stage of disease. The width but not the depth of surface ulceration significantly correlated with survival. The median ulcer depth was 0.08 mm (range 0.01-1.2 mm). In those few lesions with ulcer craters more than 0.2 mm in depth, the melanomas were so thick they had the same poor prognosis regardless of whether thickness was measured to the base of the ulcer or to the top of the lesion. The Breslow microstaging method of measuring thickness is therefore a valid prognostic indicator, even for ulcerated lesions. The incidence of ulceration for the entire patient group ranged from 12.5% for melanomas less than 0.76 mm thickness to 72.5% for melanomas greater than 4.0 mm thick (P of correlation = 0.0001); from 12% for Level II invasion to 63% for Level V lesions (P = 0.005); from 23% for superficial spreading growth patterns to 49% for nodular and 74% for polypoid lesions (P = 0.0001); and from 27% for lesions with a heavy lymphocyte infiltration to 60% for minimal or absent host response (P = 0.005). There was no significant correlation with anatomic location, pigmentation of the melanomas, or with the patient's age and sex. Since ulceration appears to have such an important influence on survival rates, this parameter should be considered as a stratification criterion in clinical trials and accounted for when analyzing results of melanoma treatment.

Entities:  

Mesh:

Year:  1980        PMID: 7388745     DOI: 10.1002/1097-0142(19800615)45:12<3012::aid-cncr2820451223>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  49 in total

1.  Gender-related differences in outcome for melanoma patients.

Authors:  Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

2.  Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain.

Authors:  José Antonio Avilés-Izquierdo; Pablo Lázaro-Ochaita
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

3.  High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.

Authors:  Szu-Ying Chin; Pei-Ru Wu; Yi-Hsien Shih; Chung-Min Yeh; Woan-Ruoh Lee; Shing-Chuan Shen; Kun-Tu Yeh; Ming-Chung Jiang; Jonathan Te-Peng Tseng
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.

Authors:  Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Piotr Waloszczyk; Marek Masiuk; Jaroslaw Wejman; Justyna Szumilo; Markku Miettinen
Journal:  Mod Pathol       Date:  2019-02-13       Impact factor: 7.842

Review 5.  Molecular pathology of cutaneous melanoma.

Authors:  Léon C van Kempen; Margaret Redpath; Caroline Robert; Alan Spatz
Journal:  Melanoma Manag       Date:  2014-12-04

6.  Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Andrzej T Slominski
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

7.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

8.  Stage III thick (>4.0 mm) lower extremity melanoma: is timing of lymph node involvement a prognostic factor?

Authors:  Krzysztof Herman; Wojciech M Wysocki; Piotr Skotnicki; Jacek Tabor; Elebieta Luczyńska; Andrzej L Komorowski
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

9.  Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat.

Authors:  C L Day; T J Harrist; F Gorstein; A J Sober; R A Lew; R J Friedman; B S Pasternack; A W Kopf; T B Fitzpatrick; M C Mihm
Journal:  Ann Surg       Date:  1981-07       Impact factor: 12.969

10.  Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology.

Authors:  Anna Batistatou; Martin G Cook; Daniela Massi
Journal:  Virchows Arch       Date:  2009-04-08       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.